SCHOTT PHARMA AG & CO KGAA
Commented by Carsten Mainitz on February 12th, 2026 | 07:55 CET
Watch out! Gerresheimer slumps 30%, NEO Battery Materials as a game changer, Schott Pharma surprises positively
Many stories of success and failure are written on the stock market. NEO Battery Materials, the game changer in battery technology, is particularly exciting. The Canadian company offers manufacturers of drones, robots, and electric vehicles customizable high-performance batteries produced in the West. With its innovative approach, the company is setting new standards in terms of performance, charging speed, and price, thereby addressing a huge market that experts estimate will grow to around USD 30 billion by 2032. The examples of Gerresheimer and Schott Pharma show how differently companies in the same industry can develop: Schott exceeded market expectations in the first quarter, while Gerresheimer shocked the markets once again.
Read
Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST
Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization
According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.
Read
Commented by Nico Popp on September 27th, 2023 | 07:10 CEST
Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics
High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!
Read